PFBT
JANX icon

Parkside Financial Bank & Trust’s Janux Therapeutics JANX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$278 – 2754
2026
Q1 		$278 Hold
20
– – ﹤0.01% 2624
2025
Q4 		$276 Buy
+20
New +$470 ﹤0.01% 2624

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Parkside Financial Bank & Trust's JANX Position: Q2 2026 in Review

Parkside Financial Bank & Trust sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 20 shares — an estimated $278 sold.

Parkside Financial Bank & Trust first reported a position in JANX in Q4 2025 and held it in 2 quarters. The position peaked at $278 in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Parkside Financial Bank & Trust reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 20 Janux Therapeutics shares in Q2 2026, an estimated $278.
  • Parkside Financial Bank & Trust first reported a position in Janux Therapeutics in Q4 2025 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Janux Therapeutics position peaked at $278 in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.